nkg2d car-nk
Cell therapyexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 10, 2021 (NCT05213195)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - KLRK1
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07021534 | Phase 1 | Jun 10, 2025 | Zhejiang University |
| NCT06856278 | Phase 1/Phase 2 (Phase 2) | Feb 22, 2025 | Zhejiang University |
| NCT05734898 | N/A | Mar 31, 2023 | Government of China, Zhejiang University |
| NCT05776355 | N/A | Mar 31, 2023 | Chinese Academy of Medical Sciences, Government of China |
| NCT05213195 | Phase 1 | Dec 10, 2021 | Zhejiang University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Zhejiang University | Academic/Hospital | 4 | 4 | 3 | 2021 |
| Government of China | Government | 2 | 1 | 1 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1